Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Ex-SAC trader points to Cohen testimony in insider trading case

12/07/2013 | 12:45pm EDT
Mathew Martoma leaves Manhattan Federal Court after facing charges on an insider trading scheme in New York

(Reuters) - A former SAC Capital Advisors trader, set to go on trial next month on insider trading charges, wants to cite in court some 2012 testimony given by the hedge fund's founder Steven Cohen, claiming it rebuts the government's case.

Mathew Martoma, the ex-SAC portfolio manager is scheduled for trial on January 6. He filed court papers late Friday seeking to use testimony given by Cohen to the U.S. Securities and Exchange Commission in May 2012.

Martoma contends the testimony will show he had nothing to do with decisions to trade in Elan Corp and Wyeth in 2008.

Filed in U.S. District Court in New York, the Martoma documents showed how extensively investigators questioned Cohen about the trading at the center of the case against Martoma, who was charged in November 2012 with insider trading in what is said to be the most lucrative such U.S. scheme ever.

Prosecutors contend Martoma got nonpublic information from a physician about a clinical trial of an Alzheimer's drug, and then used that information to help CR Intrinsic Investors, an SAC division, avoid $276 million in losses through the sale of securities for Elan and Wyeth, now owned by Pfizer Inc.

Martoma's case will go before a jury not long after the expected conclusion of a trial in New York of another SAC portfolio manager, Michael Steinberg. He is accused of trading in Dell Inc and Nvidia Corp, based on inside information.

Once a $14 billion hedge fund, SAC Capital agreed last month to pay $1.2 billion and plead guilty to fraud charges as part of the insider trading probe. Cohen, who has not been criminally charged, faces an SEC administrative action accusing him of failing to supervise Martoma and Steinberg and prevent insider trading.


The excerpts of Cohen's testimony came in a wave of pre-trial motions by Martoma's lawyers on Friday night, seeking to limit what is presented at trial. Martoma wants to exclude evidence about SAC's sale of Wyeth stock and about the way the hedge fund sold Elan and Wyeth securities.

Alternatively, Martoma's lawyers are seeking to introduce Cohen's SEC testimony at trial. Cohen is expected to assert his constitutional rights and not be available to testify at trial, Martoma's lawyers said.

Jonathan Gasthalter, a spokesman for SAC, did not immediately respond to a request for comment on Saturday.

In his testimony, Cohen told SEC investigators that he made the decision to sell Wyeth securities after consulting with Wayne Holman, a former SAC trader who went on to establish his own hedge fund, Ridgeback Capital Management.

Cohen testified that he had considered Holman "a great healthcare investor recommendations are very important to me." Holman had a $20 million consulting deal with SAC that Cohen said he approved because "he's worth it."

Martoma's lawyers contend the testimony makes clear that Holman, rather than their client, was the reason Cohen decided to sell SAC's Wyeth position in 2008. The week of the trade, Cohen said he spoke with Holman "at some point and he was telling me he was selling his Wyeth."

A lawyer for Holman did not immediately respond to a request for comment on Saturday.


In the court filings, Martoma's lawyers also contend that Cohen's testimony clearly establishes that Martoma had nothing to do with the actual trading strategies used by SAC in trading Wyeth and Elan. In his testimony, Cohen said he had decided to short Elan to hedge SAC's long exposure in Wyeth.

"Generally, what I remember was selling Wyeth and then deciding to hedge out my exposure in Wyeth by shorting Elan," Cohen testified. "It was sort of imperfect. I was estimating the ratio that I would need to sell one against the other, but that's what I did."

The case is U.S. v. Martoma, U.S. District Court, Southern District of New York, No. 12-00973.

(Reporting by Nate Raymond; Editing by Kevin Drawbaugh and Gunna Dickson)

By Nate Raymond

Stocks treated in this article : Pfizer Inc., NVIDIA Corporation, Elan Corporation, plc

ę Reuters 2013
Stocks mentioned in the article
ChangeLast1st jan.
ELAN CORPORATION LTD -0.39% 12.71 End-of-day quote.0.00%
All news about PFIZER INC
12:22aEU Health Agency To Decide On Pfizer-BioNTech's COVID-19 Booster In October
12:06aAP NEWS IN BRIEF AT 12 : 04 a.m. EDT
09/23NEWS HIGHLIGHTS : Top Company News of the Day
09/23PFIZER : CDC panel recommends Pfizer booster shot for those over 65, high-risk groups
09/23Healthcare Shares Gain as Covid-19 Developments Continue -- Healthcare Roundup
09/23U.S. CDC director breaks with panel, backs COVID-19 boosters for high-risk workers
09/23U.S. CDC advisers recommend COVID-19 vaccine boosters for 65 and older, high risk
09/23PFIZER : CDC Advisory Unanimously Recommends Pfizer/BioNTech COVID Booster For Adults 65 Y..
09/23PFIZER : Keeps Quarterly Cash Dividend at $0.39 a Share, Payable Dec. 6 to Shareholders of..
09/23MODERNA : EU drugs regulator to decide on Pfizer vaccine booster in early October
More news
Analyst Recommendations on PFIZER INC
More recommendations
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON4.75%431 543
ROCHE HOLDING AG10.05%322 644
PFIZER, INC.19.40%246 414
NOVO NORDISK A/S50.62%232 291